Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine

Clinical Chemistry

Volumn 50, Issue 5, 2004, Pages 857-866

  Kageyama, Susumu ^a   Isono, Takahiro ^a   Iwaki, Hideaki ^a   Wakabayashi, Yoshihiko ^a   Okada, Yusaku ^a   Kontani, Keiichi ^a   Yoshimura, Koji ^b   Terai, Akito ^b   Arai, Yoichi ^c   Yoshiki, Tatsuhiro ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; PROTEOMICS; TISSUE DISTRIBUTION; TISSUE LEVEL; TWO DIMENSIONAL ELECTROPHORESIS; URINALYSIS;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CALRETICULIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN ISOFORMS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 11144356519     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.027425     Document Type: Article

References (44)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Lee R, Droller MJ. Natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000;27:1-13.
3. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zeitman AL. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol 1999;162:445-51.
4. Brown FM. Urine cytology. Is it still the gold standard for screening? Urol Clin North Am 2000;27:25-37.
5. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001;165:600-11.
6. Mungan NA, Vriesema JLJ, Thomas CMG, Kiemeney LALM, Witjes JA. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology 2000;56:787-92.
7. Celis JE, Østergaard M, Rasmussen HH, Gromov P, Gromova I, Varmark H, et al. A comprehensive protein resource for the study of bladder cancer: http://biobase.dk/cgi-bin/celis. Electrophoresis 1999;20:300-9.
8. Celis JE, Rasmussen HH, Vorum H, Madsen P, Honoré B, Wolf H, et al. Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol 1996;155:2105-12.
9. Ostwald TJ, MacLennan DH. Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J Biol Chem 1974; 249:974-9.
10. Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M. Calreticulin: one protein, one gene, many functions. Biochem J 1999;344:281-92.
11. Conway EM, Liu L, Nowakowski B, Steiner-Mosonyi M, Ribeiro SP, Michalak M. Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation. J Biol Chem 1995;270:17011-6.
12. Heal R, McGivan J. Induction of calreticulin expression in response to amino acid deprivation in Chinese hamster ovary cells. Biochem J 1998;329:389-94.
13. Franzén B, Linder S, Alaiya AA, Eriksson E, Uruy K, Hirano T, et al. Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins. Br J Cancer 1996;73:1632-8.
14. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997;18:2832-41.
15. Yoon G-S, Lee H, Jung Y, Yu E, Moon H-B, Song K, et al. Nuclear matrix of calreticulin in hepatocellular carcinoma. Cancer Res 2000;60:1117-20.
16. Yu L-R, Zeng R, Shao X-X, Wang N, Xu Y-H, Xia Q-C. Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry. Electrophoresis 2000;21:3058-68.
17. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, et al. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 2000;21:1-9.
18. Ramsamooj P, Notario V, Dritschilo A. Enhanced expression of calreticulin in the nucleus of radioresistant squamous carcinoma cells in response to ionizing radiation. Cancer Res 1995;55: 3016-21.
19. Wildgruber R, Harder A, Obermaier C, Boguth G, Weiss W, Fey SJ, et al. Towards higher resolution: two-dimensional electrophoresis of Saccharomyces cerevisiae proteins using overlapping narrow immobilized pH gradients. Electrophoresis 2000;21:2610-6.
20. Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS, Mische SM. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis 1999;20:601-5.
21. Isono T, Tanaka T, Kageyama S, Yoshiki T. Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 2002;48:2187-94.
22. Yuasa T, Yoshiki T, Tanaka T, Kim C-J, Isono T, Okada Y. Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma. Jpn J Cancer Res 1998;89:879-82.
23. Yuasa T, Yoshiki T, Isono T, Tanaka T, Hayashida H, Okada Y. Expression of transitional cell-specific genes, uroplakin Ia and uroplakin II, in the peripheral blood of metastatic patients. Int J Urol 1999;6:286-92.
24. Lu J-J, Kakehi Y, Takahashi T, Wu X-X, Yuasa T, Yoshiki T, et al. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res 2000;6:3166-71.
25. Kageyama S, Yoshiki T, Isono T, Tanaka T, Kim C-J, Yuasa T, et al. High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn J Cancer Res 2002;93:523-31.
26. Jain KK. Application of laser capture microdissection to proteomics. Methods Enzymol 2002;356:157-67.
27. Celis A, Rasmussen HH, Celis P, Basse B, Lauridsen JB, Ratz G, et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 1999;20:355-61.
28. Johnson S, Michalak M, Opas M, Eggleton P. The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol 2001;11:122-9.
29. Kausch I, Böhle A. Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol 2001;39:498-506.
30. Ross JS, Cohen MB. Detecting recurrent bladder cancer: new methods and biomarkers. Expert Rev Mol Diagn 2001;1:39-52.
31. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altierl DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
32. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol 2001;165: 1067-77.
33. Boman H, Hedelin H, Holmäng S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002;167:80-3.
34. Friedrich MG, Hellstern A, Hautmann SH, Graefen M, Conrad S, Huland E, et al. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA stat and NMP22 tests. J Urol 2002;168:470-7.
35. Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001;166:470-5.
36. Mian C, Lodde M, Haitel A, Vigl EE, Marberger M, Pycha A. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 2000;55:223-6.
37. Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E. A comparison of urinary nuclear matrix protein-22 and bladder tumor antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int 2001;88:692-701.
38. Sánchez-Carbayo M, Urrutia M, Silva JM, Romani R, González de Buitrago JM, Navajo JA. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, cyfra 21-1 and NMP22 for evaluating symptomatic patients at risk bladder cancer. J Urol 2001;165:1462-7.
39. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002;89:369-73.
40. Öge Ö, Kozaci D, Gemalmaz H. The BTA stat test is nonspecific for hematuria: an experimental hematuria model. J Urol 2002;167: 1318-20.
41. Atsü N, Ekici S, Öge Ö, Ergen A, Hasçelik G, Özen H. False-positive results of the NMP22 test due to hematuria. J Urol 2002;167: 555-8.
42. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 2001;166:75-8.
43. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-7.
44. Krause KH, Michalak M. Calreticulin. Cell 1997;88:439-43.